Molecular Analysis of Oncogenes and Resistance Mechanisms in Lung Cancer

Molecular Analysis of Oncogenes and Resistance Mechanisms in Lung and Other Thoracic Cancers

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01580982

Enrollment

500

Registered

2012-04-19

Start date

2012-01-23

Completion date

2029-01-30

Last updated

2026-02-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Neoplasms

Keywords

Oncogenes, Lung and Other Thoracic Cancers

Brief summary

The mechanisms of sensitivity and resistance to oncogene-targeted therapy can be determined from tumor tissue or tumor cell lines derived from available archival samples and/or from standard-of-care re-biopsy upon suspected tumor progression.

Detailed description

To identify baseline and treatment-related somatic changes in the tumor tissue from patients with lung and other thoracic cancers. To estimate the proportion of patients that subsequent therapy is altered based on the information acquired from such biopsies.

Interventions

None listed

Study design

Observational model

OTHER

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 85 Years

Healthy volunteers

Inclusion criteria

1. Patients undergoing investigation or treatment for thoracic cancers with oncogene-targeted therapies 2. Aged 18 years or older 3. Either a) have suspected tumor progression or other condition that dictates a standard-of-care palliative, therapeutic, or diagnostic intervention including but not limited to procedures such as bronchoscopic biopsy, computed tomography (CT) or ultra-sound (US)-guided biopsy, thoracentesis, video assisted thoracoscopic (VATS) pleurodesis, lobectomy, adrenalectomy or pleural catheter placement, providing tumor specimen appropriate molecular analysis or b) have previously had biopsy/surgical intervention with tumor tissue at University of Colorado or an outside institution available for medullar analysis. 4. Patients must have the ability to understand and willingness to sign an informed consent document.

Exclusion criteria

Design outcomes

Primary

Measure	Time frame
To identify baseline and treatment-related somatic changes in the tumor tissue from patients with lung and other thoracic cancers.	To be determined upon funding

Secondary

Measure	Time frame
To estimate the proportion of patients that subsequent therapy is altered based on the information acquired from such biopsies	To be determined upon funding

Countries

United States

Contacts

CONTACTBrandi Kubala

brandi.kubala@cuanschutz.edu303-724-1657

PRINCIPAL_INVESTIGATORErin Schenk, MD, PhD

University of Colorado, Denver

Outcome results